Alzheimer s & Dementia · 2019 · 206 citations · 33 references
MedicineNeurologyNeuroscienceAgingDementiaInflammationAlzheimer DiseaseCognitive ImpairmentDementia BiomarkersDementia DiagnosisInflammatory BiomarkersNeuroinflammationAge-related NeuroinflammationAlzheimer's Disease DiagnosisCognitive BiomarkersComplement DysregulationElderly PopulationMild Cognitive Impairment DiagnosisMild Cognitive Impairment ProgressionOutcome Prediction
INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. METHODS: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. RESULTS: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). DISCUSSION: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
33
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne et al. · Nature · 2018 · 1.7K citations · Full text